CEL-SCI Corporation (NYSE:CVM) today announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*. The findings were presented by the Company’s Chief Scientific Officer and developer of Multikine, Dr. Eyal Talor, during a keynote address at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy.

The presentation highlights how pre-surgical patient stratification addresses a long-standing limitation in head and neck cancer management, where patient risk assessment traditionally relies on post-operative pathological evaluation.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.